The publication of the JAMA study sent a chill through the in vitro diagnostics industry and prompted Cepheid CEO John Bishop to post a letter to his company’s Web site addressing the study and affirming Cepheid’s financial guidance for 2008. Cepheid has built its business on the GeneXpert molecular diagnostics platform and its MRSA screening test. Last year, revenues for the clinical product sales segment of Cepheid’s business, which accounted for 52 percent of total 2007 product sales of $116.5 million, were primarily driven by the U.S. market launch of the Xpert MRSA test in April 2007.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

April 2008 - Table of Contents

DTTR April 2008 (full PDF issue)

JAMA Study Sends Chill Through IVD Market

Immucor Bets on Blood Genotyping

Third Wave Sees Clinical Revenue Grow 25% in '07

NEJM Study Probes Pharmacogenomics of Warfarin Metabolism

PerkinElmer Acquires Pediatrix’s Newborn Screening Lab

New Bioimaging System Promises Improved HER2 Testing

Ikonisys Boosts Automated FISH Platform with New Reference Lab

Quidel RSV Test Gets CLIA Waiver

Abbott to Co-Develop Pharmacogenomic Test for Lung Cancer Drug

Quest Diagnostics Signs Onto Google Health EHR

ACLA Presses SACGHS for Clarification on Genetic Testing Oversight

Beckman Coulter Launches High-Volume Testing System

IVD Stocks Fall 7%; Inverness Plummets 33%

Lung Cancer-Focused Allegro Diagnostics Raises $4 Million